// Index Comparison
ACCE Clean Energy vs ACCE Biotech Catalysts
Head-to-head: performance, risk profile, and constituent overlap between two ACCE indices.
US
ACCE Clean Energy →
Energy transition infrastructure: solar, wind, storage, and grid modernization. Policy tailwinds meet declining unit economics.
US
ACCE Biotech Catalysts →
Binary catalyst pipeline — FDA approvals, late-stage trial readouts, and M&A targets. High conviction names with visible catalysts.
ACCE Clean Energy — risk
Volatility 30d+36.9%
Volatility 90d+39.9%
Sharpe 90d-0.75
Max drawdown-19.2%
Beta vs ICLN0.92
ACCE Biotech Catalysts — risk
Volatility 30d+21.6%
Volatility 90d+25.2%
Sharpe 90d-1.05
Max drawdown-13.4%
Beta vs SPY0.91
Constituent overlap
0 stocks held by both indices (out of 5 and 6)
Top sectors — ACCE Clean Energy
Technology65.9%
Utilities34.1%
Top sectors — ACCE Biotech Catalysts
Healthcare100.0%
ACCE Verdict
ACCE Biotech Catalysts has outperformed ACCE Clean Energy since inception, losing 7.6% versus Clean Energy's 9.91% decline, though both have significantly lagged the benchmark's 4.74% gain.
Biotech Catalysts shows superior risk management with 25.2% volatility compared to Clean Energy's extreme 39.9%, though both carry negative Sharpe ratios with Biotech's -1.05 actually worse than Clean Energy's -0.75 due to consistently poor returns relative to risk taken.
These indices share virtually no overlap, representing distinct thematic bets on different transformation cycles — Clean Energy targeting the energy transition infrastructure buildout while Biotech Catalysts focuses on binary pharmaceutical development outcomes.
**Verdict:** Clean Energy suits investors seeking leveraged exposure to the energy transition despite current headwinds from higher rates and supply chain issues, accepting massive 39.9% volatility for potential policy-driven upside. Biotech Catalysts fits investors wanting concentrated exposure to pharmaceutical innovation cycles with more manageable 25.2% volatility, banking on FDA approvals and M&A activity. Both require strong conviction given their significant underperformance, but Biotech's lower volatility and smaller maximum drawdown of 13.4% versus Clean Energy's 19.2% makes it the more palatable speculative play for risk-conscious thematic investors.